 |
|
|
|
|
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
 |
|
|
|
|
|
 |
|
|
|
|
Saura C. on PAPER: Winton MJ. et al., 2011, There is compelling evidence that Aβ generated from the sequential cleavage of APP by... 20 Jun 2011.
|
|
|
 |
|
|
Saura C. on PAPER: Caccamo A. et al., 2010, This is an interesting study that provides evidence that Aβ-induced memory deficits in 3xTg-AD... 22 Dec 2010.
|
|
|
|
|
|
Saura C. on NEWS: Presenilins, Ryanodine Receptors—Conspirators in Neurotransmission?, In a new study from Jie Shen’s lab, C. Zhang et al. provide compelling evidence that presenilins... 17 Aug 2009.
|
|
|
|
|
|
Saura C. on LIVE DISCUSSION: Presenilin Loss of Function—Plan B for AD?, Jie Shen and Ron Kelleher’s PNAS Perspective summarizes experimental data from several... 8 Feb 2007.
|
|
|
|
|
|
Saura C. on LIVE DISCUSSION: Gain or Loss of Function—Time to Shake up Assumptions on γ-Secretase in Alzheimer Disease?, The mechanisms by which FAD-linked PS mutations cause memory loss and neurodegeneration are by... 19 Apr 2006.
|
|
|
|
|
|
Saura C. on NEWS: Presenilins Work Overtime to Control Akt, Tau, and Aβ—n-3 Fatty Acids Aid and Abet, Kang and colleagues described a new role of presenilins on the highly conserved ERK signaling... 26 Jul 2005.
|
|
|
|
|
|
Saura C. on PAPER: Ishikura N. et al., 2005, Notch signaling is a highly conserved pathway that plays essential roles in cell proliferation... 11 Jan 2005.
|
|
|
|
|
|
Saura C. on NEWS: Notch and Memory: More Trouble for γ-Secretase Inhibition?, Notch signaling plays a crucial role on cell fate specification during neuronal development in ... 22 Jun 2004.
|
|
|
|
|
|
Saura C. on PAPER: Feng R. et al., 2004, Feng et al. describe cortical degeneration in the forebrain of mice lacking the Alzheimer’s... 24 May 2004.
|
|
|
|
|
|
|
1 to 9 of 9 results |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
The ALS Forum is a web-based collaborative effort to bring together valuable ALS-related resources for use by researchers worldwide in both academia and industry-based settings.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Should the FDA be allowed to use data from overseas clinical trials? |
|
|
|
|
|
|
|
|
|
|
|
Absolutely, we are running out of viable subjects in the U.S. |
|
|
|
|
|
|
 9 |
|
|
|
|
|
|
|
|
|
|
|
Yes, so long as the data is reliable |
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
No, the trials are not as rigorous |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
No, the data should be repeated in the U.S. |
|
|
|
|
|
|
5 |
|
|
|
|
|
|
|
|
|
|
|
No, the drug sponsors are just trying to cut corners |
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
Responses: 51 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
Archived Polls |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
 Antibodies
Cell Lines
Collaborators
Papers
Research Participants
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Home
See our latest Webinar: 
